96 / 132
Food and Drug Administration
96
manufacturers regarding application for the Certificate of suitability to the monographs of the
European Pharmacopoeia (CEP). It is hoped that these activities will make Taiwan's pharmaceutical
industries more competitive, and build an environment that is beneficial for the general public, the
industry, and the government (Figure 9-3).
(2) According to
the Arrangement between Taiwan and Japan for
the
Framework of Cooperation on the
Medical Products Regulation
signed on 5 November 2013, Japan hosted the
2nd Joint Conference
of Taiwan and Japan on Medical Products
Regulation on 31 October and 1 November 2014 in Tokyo
(Figure 9-4). Open sessions and closed door meetings on the areas of pharmaceuticals, national health
insurance, and medical devices were convened to strengthen bilateral exchanges and regulatory
convergence between Taiwan and Japan. Cooperation details were also discussed. On the topic of
pharmaceutical products, both parties have established their respective working groups to cooperate on
five topics including new drugs and generic drugs review, management of OTC drugs, and cooperation
Figure 9-4
The Second Joint Conference of Taiwan and Japan on Medical Products Regulation
Figure 9-3
Hosting the joint symposium of TFDA and EDQM in Taipei